A Phase 3 interventional study of Rimonabant and Placebo (for Rimonabant) in Carotid Artery Plaque, Arteriosclerosis and Obesity, sponsored by Sanofi. Terminated at 6 sites in 6 countries. Open to participants aged 55 Years and older. Per ClinicalTrials.gov, last updated 2016-05-20.
Sponsored by Sanofi · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 83 studies in Carotid Stenosis with a site in United States — 5 open to participants now, 12 under way, none of them phase 3. Carotid Stenosis · United States.
Among the 83 studies in Carotid Stenosis with a site in United States, this one is the 6th largest by enrollment of the 52 interventional ones that give a count, is one of 2 that started in 2005, is one of 6 in phase 3, and was the 8th registered.
366 studies on the registry are indexed under Carotid Stenosis; 86 are open to participants now.
Browse Carotid Stenosis studies →5 of the 83 studies in Carotid Stenosis with a site in United States are open now. Recruiting first, the newest first:
InspireMD · Sites in United States
Ages 18–79
Mayo Clinic · Sites in United States
Ages 18+
VA Office of Research and Development · Sites in United States
Ages 18–89 · Healthy volunteers
University of California, San Diego · Sites in United States
Ages 18+
Vibrant Medical Ltd. · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 61 Carotid Stenosis studies recruiting now, 39 (64%) set no upper age limit and none (0%) stop at 75 or younger; 4 take children under 18; 4 take healthy volunteers.
This study: 55 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
83 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 10 · Phase 3 7 · Phase 4 5
First in 1993; this study’s year is marked. 2 started in 2005.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 661 is above the median of 103 across 191 interventional studies indexed under Carotid Stenosis.
Median enrollment 71 across the 52 interventional studies, 114 across the 31 observational. Of the 60 that completed or were terminated, 22 (37%) have results posted.
This tab as a report to print or save as PDF → With an account.
23 of 83 have an industry lead sponsor. The 10 most frequent:
Sanofi is the lead sponsor of 1,558 studies on the registry; 89 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 123 (60%) have results posted.
Sanofi has 1 study filed under Carotid Stenosis — fewer than ten, so there is no comparison to draw.
4 of the studies in Carotid Stenosis with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06653387InspireMDA Single-arm, Pivotal Study to Evaluate Acute Device and Technical Success of the CGuard Prime Carotid Stent System When Used in Conjunction to the ENROUTE Transcarotid Neuroprotection System in Patients Undergoing Carotid Artery Stenting Via the Transcarotid Artery Revascularization Approach | 2026-11-20 |
| NCT07851389Vibrant Medical Ltd.A First-in-Human Feasibility Study of the Vibrant Stroke Detection Technology During Carotid Endarterectomies | 2027-03 |
| NCT04063709University of North Carolina, Chapel HillTranscutaneous ARFI Ultrasound for Differentiating Carotid Plaque With High Stroke Risk | 2027-08 |
| NCT05465122Mayo ClinicCREST-2 Long-term Observational Extension Study | 2027-08-31 |
Add all 4 to your calendar (.ics) → With an account.
Among the 83 studies in Carotid Stenosis with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Objectives:
This is a Phase III, prospective, multicentre, multinational, randomized, double-blind, placebo-controlled, 2-arm parallel group trial (rimonabant 20-mg od vs placebo). There will be a three-stage screening process including successively a Screening visit, a Screening CIMT and a validation of the Screening CIMT by the Imaging Core Laboratory. Patients complying with all inclusion and exclusion criteria will be randomized in one of the 2 treatment groups less than two weeks after Screening visit. Study drug (rimonabant 20 mg od or matching placebo) will be administered during 30 to 32 months. At inclusion, patients will be counseled to follow a mild hypocaloric diet, to increase their exercise level, and to stop smoking (if smokers). Glucose/lipid parameters will be assessed at Baseline and every 6 months until the Month 30 visit. CIMT will be performed at Baseline and every 6 months until final assessment at Month 30 (primary endpoint).A post-treatment follow-up visit at Month 35 will allow the collection of all adverse events and cardiovascular outcomes occurring after last study drug administration
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Metabolic syndrome diagnosed on the basis of at least two of the following additional risk factors:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Rimonabant 20 mg once daily
Drug: Rimonabant
Placebo (for Rimonabant) once daily.
Drug: Placebo (for Rimonabant)
Tablet, oral administration
Also known as: SR141716, Acomplia
Tablet, oral administration
Absolute change from baseline in averaged per patient carotid artery intima-media thickness (CIMT)
Time frame: Month 30
First occurrence of any component of stroke/myocardial infarction (MI)/cardiovascular death
Time frame: From randomization to Month 35
First occurrence of any component of stroke/MI/cardiovascular death/hospitalization for revascularization procedure, unstable angina, transient ischemic attack (TIA)
Time frame: From randomization to Month 35
The record gives a start of Aug 2005, a primary completion of Apr 2009 and a completion of Apr 2009. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Apr 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Rimonabant